A Clinical Trial to Compare Forms of MK-1167 in Healthy People (MK-1167-011)

A Two-Period, Open-label, Fixed-Sequence Study to Evaluate the Single-Dose Pharmacokinetics of Two Formulations of MK-1167 in Healthy Participants

Researchers are looking for new ways to treat Alzheimer's disease (AD). AD is a brain disease that causes a gradual decline in memory, thinking, and ability to carry out daily tasks. MK-1167 is a study medicine designed to treat symptoms of AD. Before giving a study medicine to people with a health condition, researchers first do studies in healthy people to find a safe dose of the study medicine.

The goals of the trial are to learn:

• What happens to different forms of MK-1167 in a healthy person's body over time
• About the safety of MK-1167 and if people tolerate it

Inclusion Criteria:

• Is in good health
• Has a body mass index (BMI) ≥18 and ≤ 32 kg/m^2, inclusive

Exclusion Criteria:

• Has a history of clinically significant endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological abnormalities or diseases
• Is a smoker and/or has used nicotine or nicotine-containing products within the past 3 months.